← ANALYST RATINGS · TIPRANKS
Septerna, Inc. (SEPN): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $52.88, the highest $60.00, the lowest $46.00. The average is +45.5% from the last price of $36.35.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $38.00 → $39.00+2.6% | Hold | +7.3% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $39.00 → $38.00−2.6% | Hold | +4.5% | Reiterated | 15.10.26on TipRanks 14:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $40.00 → $39.00−2.5% | Hold | +7.3% | Downgrade | 14.10.26on TipRanks 08:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $42.00 → $41.00−2.4% | Buy | +12.8% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $40.00 → $39.00−2.5% | Hold | +7.3% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $39.00 → $40.00+2.6% | Hold | +10.0% | Downgrade | 09.10.26on TipRanks 11:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $39.00 → $40.00+2.6% | Hold | +10.0% | Downgrade | 09.10.26on TipRanks 11:07 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $38.00 → $39.00+2.6% | Hold | +7.3% | Reiterated | 09.10.26on TipRanks 11:07 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $37.00 → $38.00+2.7% | Hold | +4.5% | Reiterated | 09.10.26on TipRanks 11:07 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $41.00 → $42.00+2.4% | Buy | +15.5% | Reiterated | 09.10.26on TipRanks 11:07 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $39.00 → $40.00+2.6% | Hold | +10.0% | Reiterated | 09.10.26on TipRanks 11:07 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $40.00 → $41.00+2.5% | Buy | +12.8% | Reiterated | 08.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $38.00 → $39.00+2.6% | Hold | +7.3% | Reiterated | 08.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $40.00 → $39.00−2.5% | Hold | +7.3% | Downgrade | 07.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $40.00 → $39.00−2.5% | Hold | +7.3% | Downgrade | 07.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $39.00 → $38.00−2.6% | Hold | +4.5% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $38.00 → $37.00−2.6% | Hold | +1.8% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $42.00 → $40.00−4.8% | Buy | +10.0% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $40.00 → $38.00−5.0% | Hold | +4.5% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $50.00 | Buy | +37.6% | Reiterated | 09.09.26on TipRanks 14:00 | +2.1%next day 0.0% · 5 days +2.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $40.00 | Hold | +10.0% | Downgrade | 08.09.26on TipRanks 20:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $40.00 | Hold | +10.0% | Downgrade | 08.09.26on TipRanks 20:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $39.00 | Hold | +7.3% | Reiterated | 08.09.26on TipRanks 20:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $38.00 | Hold | +4.5% | Reiterated | 08.09.26on TipRanks 20:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $42.00 | Buy | +15.5% | Reiterated | 08.09.26on TipRanks 20:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $40.00 | Hold | +10.0% | Reiterated | 08.09.26on TipRanks 20:05 | — | |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $38.00 → $48.00+26.3% | Buy | +32.0% | Reiterated | 19.08.26on TipRanks 09:30 | +0.1%next day −6.3% · 5 days −8.0% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $43.00 → $46.00+7.0% | Buy | +26.5% | Reiterated | 16.08.26on TipRanks 13:50 | −0.2%next day −0.2% · 5 days −7.1% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | $43.00 → $59.00+37.2% | Buy | +62.3% | Reiterated | 13.08.26on TipRanks 22:25 | −1.2%next day −0.2% · 5 days −8.7% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $40.00 → $60.00+50.0% | Buy | +65.1% | Reiterated | 12.08.26on TipRanks 06:35 | +0.6%next day −7.0% · 5 days −8.4% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | — | Buy | — | Reiterated | 11.08.26on TipRanks Aug 12 03:55 | +23.3%next day +0.6% · 5 days −7.9% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $49.00 | Buy | +34.8% | Assigned | 11.08.26on TipRanks 09:10 | +23.3%next day +0.6% · 5 days −7.9% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $45.00 → $51.00+13.3% | Buy | +40.3% | Reiterated | 11.08.26on TipRanks 06:55 | +23.3%next day +0.6% · 5 days −7.9% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $60.00 | Buy | +65.1% | Reiterated | 10.08.26on TipRanks Aug 11 07:55 | +0.1%next day +23.3% · 5 days +13.8% | ↗ |
| Asthika Goonewardene★★★★★★★★★★#5130 · hits 41% · avg +2.0% | Truist Financial | — | Buy | — | Reiterated | 02.03.26on TipRanks 08:15 | −1.4%next day −0.9% · 5 days +2.6% | ↗ |
| Catherine Novack★★★★★★★★★★#905 · hits 41% · avg +25.1% | JonesTrading | $43.00 | Buy | +18.3% | Initiated | 23.12.25on TipRanks 07:40 | −4.7%next day +4.0% · 5 days −0.4% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Septerna, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $52.88 at a price of $39.13 (+35.1%); now: $52.88 at $36.35 (+45.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 8 | 7 | 4 | 1 | 1 |
| Buy | 8 | 5 | 6 | 14 | 13 | 10 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 25.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.41 (from $-0.91 to $-0.17). Last quarter: $-0.29.
Sales
Next quarter’s sales estimate — $21M (from $0M to $32M). Last quarter: $27M.
Best top-analyst consensus in the sector · General
About Septerna, Inc.
- CEO: Jeffrey T. Finer
- Employees: 123
- 250 East Grand Avenue, South San Francisco, CA, 94080, US
- septerna.com
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 36 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗